NDLI: Effects of fetal exposure to maternal chemotherapy.

Please wait, while we are loading the content...

Year: 2017 Volume: 19

Year: 2016 Volume: 18

Year: 2015 Volume: 17

Year: 2014 Volume: 16

Year: 2013 Volume: 15

Year: 2013 Volume: 15 Issue: 6

Year: 2013 Volume: 15 Issue: 5

Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents.

Management of diffuse pontine gliomas in children: recent developments.

Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure.

Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs.

Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.

Glucocorticoids in the management of systemic juvenile idiopathic arthritis.

Effects of fetal exposure to maternal chemotherapy.

13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.

Year: 2013 Volume: 15 Issue: 4

Year: 2013 Volume: 15 Issue: 3

Year: 2013 Volume: 15 Issue: 2

Year: 2013 Volume: 15 Issue: 1

Year: 2012 Volume: 14

Year: 2011 Volume: 13

Year: 2010 Volume: 12

Year: 2009 Volume: 11

Year: 2008 Volume: 10

Effects of fetal exposure to maternal chemotherapy.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Dekrem, Jana Van Calsteren, Kristel Amant, Frédéric
Description	Country affiliation: Belgium Author Affiliation: Dekrem J ( Lab of Experimental Gynaecology, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.)
Abstract	Approximately 1 in 1,000-2,000 pregnancies are complicated by cancer. Today, different treatment options are considered as safe during pregnancy: chemotherapy, radiotherapy, surgery, or a combination of these. Surgery is considered safe during all trimesters of pregnancy; radiotherapy can be administered during the first and the second trimester, and chemotherapy after the first trimester of pregnancy. The placenta, acting as a barrier between the mother and the fetus, plays a key role in the safe administration of chemotherapy during pregnancy. A few studies have investigated the short- as well as the long-term health, general development, and cognitive and cardiac outcomes on children exposed to chemotherapy in utero. In general, these results were reassuring. Nevertheless, better safety data are required. This means data with longer follow-up periods and comparison with appropriate control groups. Moreover, important biasing factors should be taken into account when interpreting these results. Firstly, a great proportion of children were born prematurely due to the maternal condition. Preterm birth in general has been associated with cognitive impairment. Secondly, cancer during pregnancy is clearly a stressful situation, and maternal stress is associated with attention deficits. In sum, we state that chemotherapy can be administered safely after the first trimester of pregnancy. Moreover, iatrogenic prematurity in order to start postpartum administration of chemotherapy should be avoided. Nonetheless, decisions concerning treatment in these specific cases should always be made in a multidisciplinary setting with internationally recognized expertise in the coexistence of cancer and pregnancy.
File Format	HTM / HTML
ISSN	11745878
Issue Number	5
Volume Number	15
e-ISSN	11792019
Journal	Pediatric Drugs
Language	English
Publisher	Springer
Publisher Date	2013-10-01
Publisher Place	Switzerland
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Drug Therapy Discipline Pediatrics Antineoplastic Agents Adverse Effects Pregnancy Complications, Neoplastic Drug Therapy Female Humans Infant, Premature Infant, Premature, Diseases Chemically Induced Maternal-fetal Exchange Molecular Targeted Therapy Pregnancy Pregnancy Trimesters Premature Birth Prenatal Exposure Delayed Effects Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Pediatrics, Perinatology and Child Health

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in